Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
12/24/2008 | CN100445300C GLP-1 fusion protein and its preparation method and medicinal uses |
12/24/2008 | CN100445297C Amolops loloensis insulin release promoting peptide and use in producing medicine |
12/24/2008 | CN100445296C Polypeptide organic compounds and application in xenogeneic transplantation |
12/24/2008 | CN100444895C Immunomodulator for treating malignant tumor |
12/24/2008 | CN100444894C Methods and compositions for the promotion of hair growth utilizing actin binding peptides |
12/24/2008 | CN100444848C Pharmaceutical composition for improved administration of HIV gp41-derived peptides,And its use in therapy |
12/24/2008 | CN100444838C Use of inhibitors for treatment of disorders related to RTK hyperfunction |
12/24/2008 | CA2727391A1 Azapeptides as cd36 binding compounds |
12/24/2008 | CA2696615A1 Oligosaccharide chain added glp-1 peptide |
12/24/2008 | CA2692039A1 Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling |
12/24/2008 | CA2691386A1 Biological active proteins having increased in vivo and/or in vitro stability |
12/24/2008 | CA2691243A1 Thrombin inhibitor |
12/24/2008 | CA2691110A1 Modified human factor vii/viia and pharmaceutical composition containing same |
12/24/2008 | CA2691095A1 Hemostatic agents |
12/24/2008 | CA2691024A1 Fibrin gel for controlled release of pdgf and uses thereof |
12/24/2008 | CA2690734A1 Polypeptides and methods of use |
12/24/2008 | CA2690603A1 Targeted oxygen delivery via intravenous or intra-arterial infusion of oxygenated polymerized hemoglobin solutions |
12/24/2008 | CA2690449A1 Synergistic treatment of cells that express epha2 and erbb2 |
12/24/2008 | CA2690119A1 Use of taci-ig fusion protein such as atacicep for the manufacture of a medicament for treating lupus erythematosus |
12/24/2008 | CA2689588A1 Promoterless cassettes for expression of alphavirus structural proteins |
12/24/2008 | CA2687968A1 Stabilized thrombin compositions |
12/23/2008 | US7468430 Transposase and method of gene modification |
12/23/2008 | US7468427 Antibodies to PRO1275 polypeptide |
12/23/2008 | US7468426 Using lymphocytes expressing jun kinase as tools in detecting modulators for treatment of cell proliferative disorders |
12/23/2008 | US7468425 p40 protein acts as an oncogene |
12/23/2008 | US7468424 Antibody that binds to the protein; given amino acid sequence |
12/23/2008 | US7468423 Homogeneous preparations of IL-28 and IL-29 |
12/23/2008 | US7468421 Administering andothelins, or antagonist thereof, as drug or cosmetics for hair removal or wool harvesting |
12/23/2008 | US7468420 Process for purifying glycopeptide phosphonate derivatives |
12/23/2008 | US7468419 autoimmune diseases; antiarthritic agents; inflammatory bowel disorders; psoriasis; antiallergens; chronic obstructive pulmonary disease; antiallergens |
12/23/2008 | US7468388 Using 5-aceylamino-4-azido-4-nitrophenoxycarbonyloyl) -(2-oxo (1,3-dioxolan-4-yl)-5,6-dihydropyran-2-carxylic acid methyl ester; therapy for myxovirus infections; active materials; stability; long time in lungs |
12/23/2008 | US7468359 Compositions comprising oxophosphonate-based metalloproteinase inhibitors |
12/23/2008 | US7468357 Nucleosides with anti-hepatitis B virus activity |
12/23/2008 | US7468356 Modulation of insulin like growth factor I receptor expression |
12/23/2008 | US7468354 Prostate specific antigen; immobilization; antiproliferative agents; drug delivery |
12/23/2008 | US7468353 Treating idiopathic pulmonary fibrosis, hypersensitive pneumonia or diffused panbronchiolitis by administering a peptide or a polypeptide with the same biological activity as Vasoactive Intestinal Peptide or Pituitary Adenylate Cyclase-Activating Polypeptide: Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu |
12/23/2008 | US7468352 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
12/23/2008 | US7468351 Erythropoietin solution formulation |
12/23/2008 | US7468350 Glue composition for lung volume reduction |
12/23/2008 | US7468268 Nucleic acid molecules encoding osteoclastogenesis inhibitory factor proteins |
12/23/2008 | US7468267 Leucine aminopeptidase polypeptide, carboxypeptidases polypeptide; dermatophyte; degradation, hydrolysis or maturation of polypeptide substrate; Exonuclease X of Escherichia coli ( EXOX protein); fungicides; dipeptidyl peptidase IV |
12/23/2008 | US7468195 Skin treatment preparation |
12/23/2008 | US7468193 Nutritional composition against side effects of chemotherapy or radiotherapy |
12/23/2008 | US7468189 Injection of botulinum toxin types A, B, C1, D, E, F or G as analgesic for diabetes- or cancer-associated pain not associated with headache or muscle spasm |
12/23/2008 | US7468188 Multi-step therapy for injured muscles |
12/23/2008 | US7468184 Therapeutic agent for cachexia |
12/23/2008 | CA2387370C Percutaneous sorbefacients for electroporation |
12/23/2008 | CA2364499C Means and methods for fibroblast-like or macrophage-like cell transduction |
12/23/2008 | CA2339791C Methods and compositions for cloning nucleic acid molecules |
12/23/2008 | CA2334520C Treatment of immune diseases |
12/23/2008 | CA2324115C A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient |
12/23/2008 | CA2249320C Glycosylated humanized b-cell specific antibodies |
12/23/2008 | CA2219641C Diagnostic composition |
12/23/2008 | CA2212750C Humanized antibodies against cd3 |
12/23/2008 | CA2182889C Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor |
12/23/2008 | CA2158822C Therapeutic agent for rheumatic disease |
12/23/2008 | CA2105300C Process for the development of binding mini-proteins |
12/23/2008 | CA2100925C Process for preparing microspheres for the prolonged release of the lhrh hormone and its analogues, microspheres and formulations obtained |
12/18/2008 | WO2008154638A2 Antagonists of the receptor for advanced glycation end-products (rage) |
12/18/2008 | WO2008154493A2 Novel peptides that inhibit the opening of mammalian tight junctions |
12/18/2008 | WO2008154441A1 Methods for preparing diazonamides |
12/18/2008 | WO2008154350A2 Use of tight junction agonists to suppress immune responses |
12/18/2008 | WO2008154226A1 Natriuretic fusion proteins |
12/18/2008 | WO2008154151A2 Surfactant usage in lung transplantation and methods thereof |
12/18/2008 | WO2008154129A1 Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye |
12/18/2008 | WO2008154101A1 Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus |
12/18/2008 | WO2008154012A2 Treatments involving glutaredoxins and similar agents |
12/18/2008 | WO2008154004A2 Inhibition of tumor metastases using protein kinase c (pkc) inhibitors |
12/18/2008 | WO2008153933A2 Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease |
12/18/2008 | WO2008153929A1 Igf for the treatment of rett syndrome and synaptic disorders |
12/18/2008 | WO2008153788A2 Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof |
12/18/2008 | WO2008153762A2 S-nitrosothiol formulations and storage systems |
12/18/2008 | WO2008153705A2 Methods of treating, diagnosing and detecting fgf21-associated disorders |
12/18/2008 | WO2008153072A1 Gene sensitive to bone/joint disease and use thereof |
12/18/2008 | WO2008153035A1 Liposome preparation for iontophoresis comprising insulin enclosed therein |
12/18/2008 | WO2008152609A1 Interferon alpha sequential regimen for treating cancers |
12/18/2008 | WO2008152527A2 Cell-proliferation inhibiting vpg proteins, fragments or analogs thereof and their applications. |
12/18/2008 | WO2008152490A2 Loaded target-specific vesicles, method of producing the vesicles and their use in medical imaging |
12/18/2008 | WO2008152403A1 Glucagon analogues |
12/18/2008 | WO2008152401A1 Peptide slow-release formulations |
12/18/2008 | WO2008152392A2 Use of beta-gbp (galactoside binding protein) |
12/18/2008 | WO2008152262A2 Formation of proteoliposomes containing membrane proteins by means of an acellular protein synthesis system |
12/18/2008 | WO2008152178A1 Cysteine proteases inhibitors |
12/18/2008 | WO2008152140A2 Recombinant transferrin mutants |
12/18/2008 | WO2008152106A1 Pharmaceutical formulation comprising an insulin derivative |
12/18/2008 | WO2008152015A1 Composition for the improvement of functional difficulties due to articular cartilage disorders |
12/18/2008 | WO2008151841A2 Treatment for alzheimer' s disease |
12/18/2008 | WO2008151817A1 Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders |
12/18/2008 | WO2008151637A2 Neuroplastin derived peptides |
12/18/2008 | WO2008151512A1 Site-specific pegylated linear salmon calcitonin derivatives |
12/18/2008 | WO2008151449A1 Method for the treatment of atopic eczema |
12/18/2008 | WO2008151434A1 Small cationic antimicrobial peptides |
12/18/2008 | WO2008151428A1 Novel compositions for modulating mrna translation |
12/18/2008 | WO2008151388A1 Methods of initiating insulin production |
12/18/2008 | WO2008151387A1 Method of initiating cardiomyocyte differentiation |
12/18/2008 | WO2008151347A1 Ace2 polypeptide |
12/18/2008 | WO2008116116A3 Gm-csf cosmeceutical compositions and methods of use thereof |
12/18/2008 | WO2008113992A3 Gel compositions comprising urea derivatives |
12/18/2008 | WO2008110771A3 Composition comprising an il-8 blocking agent and/or a trail blocking agent for use in the treatment of liver disease and hepatic flares |
12/18/2008 | WO2008103489A3 Rna targeting compounds and methods for making and using same |